Multiple Myeloma Research Foundation - MMRF
Michael Andreini's work experience includes being the President & Chief Executive Officer at the Multiple Myeloma Research Foundation (MMRF), where they focus on accelerating a cure for multiple myeloma patients and advancing health equity. Prior to this, they served as the Chief Operating Officer at MMRF.
Before joining MMRF, Michael worked at IQVIA, a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Michael held roles such as Associate Principal, Engagement Leader, Consultant, and Associate Consultant in the Consulting Services division.
Earlier in their career, Michael worked as a Research Analyst at Fuld & Company, providing competitive strategy advice and market insights to clients. Michael also served as a Product Support Technician at Siemens Healthcare, where they contributed to clinical decision-making and treatment pathways through in-vitro and in-vivo diagnostics.
Michael Andreini earned their Bachelor of Arts degree in Chemistry and Economics from Colgate University, where they studied from 2002 to 2006. Michael later pursued further education at Harvard Business School Executive Education, where they enrolled in the program "Accelerating Innovation in Precision Medicine" in 2019. The current end year for this program is unknown.
This person is not in any offices
Multiple Myeloma Research Foundation - MMRF
We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.